I think its fair to say we have seen it at this level many times in the past, and it retraces on a technical front quite quickly towards 250. Then people will start shouting LEAK and "is it us" when in reality, the 240-260 mark is where we should be. THis is derisked.
Good to see things are progressing. But given the work they are carrying out, I don't see any substantial news landing over the next few months. Ox deal isn't substantial
Its honestly astounding how many PI's don't understand regulatory approvals yet seem to think they are experts. The fact of the matter is, CE mark is DONE, the rest is a formality. The more interesting part of the RNS is the European aspect which no one seems to be talking about!
Rise is a mixture of a technical rise and the fact that SNG works on variants. Unsustainable and can see it dipping into the high 130s and settling there. Good news nonetheless.
Its genuinely hilarious how people act on this board. We have steadily ticked pretty much every single box and people are crying over the MHRA being late to respond to US (not the other way round). Its a formality ffs. The same people that wet themselves now will be coming with rocket emojis when the RNS lands. Its pathetic.
Its coming very soon and orders will follow. Just be patient.
Great RNS, de-risking this once more. Selfishly a bit unhappy that this has moved up so quick, was hoping to liquidate some other positions to top up here in the low 100s! Nevertheless, upwards and onwards.
I think many of the antivirals they are looking at are from companies that are not British, I think someone posted a list of all of them a couple of weeks ago. I also beleive the preference is a home based antiviral, rather than hospitalised patients
Probably not. However, I have it on good authority that the government is indeed heavily stockpiling on antivirals at the moment in molecules that haven't read out PII results let alone PIII. I think this bodes well for us.
They want antivirals in place for Autumn and are buying at risk of trials failing.